Modulating osteoclasts with nanoparticles: A path for osteoporosis management?

IF 6.9 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Helena Rouco, Patricia García-García, Erik Briffault, Patricia Diaz-Rodriguez
{"title":"Modulating osteoclasts with nanoparticles: A path for osteoporosis management?","authors":"Helena Rouco,&nbsp;Patricia García-García,&nbsp;Erik Briffault,&nbsp;Patricia Diaz-Rodriguez","doi":"10.1002/wnan.1885","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoclasts are the cells responsible for the bone resorption process during bone remodeling. In a healthy situation, this process results from an equilibrium between new matrix formation by osteoblast and matrix resorption by osteoclast. Osteoporosis (OP) is a systemic bone disease characterized by a decreased bone mass density and alterations in bone microarchitecture, increasing fracture predisposition. Despite the variety of available therapies for OP management there is a growing gap in its treatment associated to the low patients' adherence owing to concerns related with long-term efficacy or safety. This makes the development of new and safe treatments necessary. Among the newly developed strategies, the use of synthetic and natural nanoparticles to modulate osteoclasts differentiation, activity, apoptosis or crosstalk with osteoblasts have arisen. Synthetic nanoparticles exert their therapeutic effect either by loading antiresorptive drugs or including molecules for osteoclasts gene regulation. Moreover, this control over osteoclasts can be improved by their targeting to bone extracellular matrix or osteoclast membranes. Furthermore, natural nanoparticles, also known as extracellular vesicles, have been identified to play a key role in bone homeostasis. Consequently, these systems have been widely studied to control osteoblasts and osteoclasts under variable environments. Additionally, the ability to bioengineer extracellular vesicles has allowed to obtain biomimetic systems with desirable characteristics as drug carriers for osteoclasts. The analyzed information reveals the possibility of modulating osteoclasts by different mechanisms through nanoparticles decreasing bone resorption. These findings suggest that controlling osteoclast activity using nanoparticles has the potential to improve osteoporosis management. This article is categorized under: Implantable Materials and Surgical Technologies > Nanomaterials and Implants Implantable Materials and Surgical Technologies > Nanotechnology in Tissue Repair and Replacement Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.</p>","PeriodicalId":23697,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"15 4","pages":"e1885"},"PeriodicalIF":6.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/wnan.1885","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 1

Abstract

Osteoclasts are the cells responsible for the bone resorption process during bone remodeling. In a healthy situation, this process results from an equilibrium between new matrix formation by osteoblast and matrix resorption by osteoclast. Osteoporosis (OP) is a systemic bone disease characterized by a decreased bone mass density and alterations in bone microarchitecture, increasing fracture predisposition. Despite the variety of available therapies for OP management there is a growing gap in its treatment associated to the low patients' adherence owing to concerns related with long-term efficacy or safety. This makes the development of new and safe treatments necessary. Among the newly developed strategies, the use of synthetic and natural nanoparticles to modulate osteoclasts differentiation, activity, apoptosis or crosstalk with osteoblasts have arisen. Synthetic nanoparticles exert their therapeutic effect either by loading antiresorptive drugs or including molecules for osteoclasts gene regulation. Moreover, this control over osteoclasts can be improved by their targeting to bone extracellular matrix or osteoclast membranes. Furthermore, natural nanoparticles, also known as extracellular vesicles, have been identified to play a key role in bone homeostasis. Consequently, these systems have been widely studied to control osteoblasts and osteoclasts under variable environments. Additionally, the ability to bioengineer extracellular vesicles has allowed to obtain biomimetic systems with desirable characteristics as drug carriers for osteoclasts. The analyzed information reveals the possibility of modulating osteoclasts by different mechanisms through nanoparticles decreasing bone resorption. These findings suggest that controlling osteoclast activity using nanoparticles has the potential to improve osteoporosis management. This article is categorized under: Implantable Materials and Surgical Technologies > Nanomaterials and Implants Implantable Materials and Surgical Technologies > Nanotechnology in Tissue Repair and Replacement Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.

Abstract Image

用纳米颗粒调节破骨细胞:骨质疏松症的治疗途径?
破骨细胞是骨重塑过程中负责骨吸收的细胞。在健康的情况下,这一过程是由成骨细胞形成新基质和破骨细胞吸收基质之间的平衡引起的。骨质疏松症(OP)是一种全身性骨病,其特征是骨密度降低和骨微结构改变,增加骨折易感性。尽管有多种可用的手术治疗方法,但由于对长期疗效或安全性的担忧,与低患者依从性相关的治疗差距越来越大。这使得有必要开发新的安全治疗方法。在新开发的策略中,使用合成和天然纳米颗粒来调节破骨细胞的分化、活性、凋亡或与成骨细胞的串扰已经出现。合成纳米颗粒通过装载抗骨吸收药物或包含破骨细胞基因调控分子来发挥其治疗作用。此外,这种对破骨细胞的控制可以通过靶向骨细胞外基质或破骨细胞膜来改善。此外,天然纳米颗粒,也被称为细胞外囊泡,已被确定在骨稳态中发挥关键作用。因此,这些系统已被广泛研究在可变环境下控制成骨细胞和破骨细胞。此外,生物工程细胞外囊泡的能力已经允许获得具有理想特性的仿生系统,作为破骨细胞的药物载体。分析的信息揭示了通过纳米颗粒减少骨吸收通过不同机制调节破骨细胞的可能性。这些发现表明,使用纳米颗粒控制破骨细胞活性具有改善骨质疏松症管理的潜力。本文分类如下:可植入材料和外科技术>纳米材料和植入物>组织修复和替代中的纳米技术>生物学中的纳米技术方法>生物学中的纳米级系统。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology NANOSCIENCE & NANOTECHNOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
16.60
自引率
2.30%
发文量
93
期刊介绍: Nanotechnology stands as one of the pivotal scientific domains of the twenty-first century, recognized universally for its transformative potential. Within the biomedical realm, nanotechnology finds crucial applications in nanobiotechnology and nanomedicine, highlighted as one of seven emerging research areas under the NIH Roadmap for Medical Research. The advancement of this field hinges upon collaborative efforts across diverse disciplines, including clinicians, biomedical engineers, materials scientists, applied physicists, and toxicologists. Recognizing the imperative for a high-caliber interdisciplinary review platform, WIREs Nanomedicine and Nanobiotechnology emerges to fulfill this critical need. Our topical coverage spans a wide spectrum, encompassing areas such as toxicology and regulatory issues, implantable materials and surgical technologies, diagnostic tools, nanotechnology approaches to biology, therapeutic approaches and drug discovery, and biology-inspired nanomaterials. Join us in exploring the frontiers of nanotechnology and its profound impact on biomedical research and healthcare.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信